Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aussie Prana’s Alzheimer’s Drug Shows Promising Early Data

This article was originally published in PharmAsia News

Executive Summary

A drug developed by Prana Biotechnology of Australia has demonstrated in an early trial a possible cure for Alzheimer's disease. The drug PBT2 works by preventing the abeta protein from combining with metals in the brain, a combination believed to cause toxic effects on the brain. The Prana-supported research was published in The Lancet medical journal. Prana is an academic spinoff of the University of Melbourne. The company's CEO, Geoffrey Kempler, said the drug could be the world's first treatment of the underlying causes of Alzheimer's. (Click here for more
Advertisement

Related Content

Rethinking Alzheimer's: Mapping Out an Approval Process
Advertisement
UsernamePublicRestriction

Register

SC069169

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel